Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation
暂无分享,去创建一个
K. Byth | P. Rowlings | M. Hertzberg | C. Forsyth | C. Underhill | Maansi Joshi | P. Crispin | A. Bayley | Gillian Huang | P. Campbell | J. Taper | M. Harvey
[1] Lizheng Shi,et al. Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data , 2018, Blood.
[2] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[3] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Gaulard,et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial , 2013, Haematologica.
[5] G. Salles,et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Tatsumi,et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Habermann,et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.
[8] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Jordi Martínez,et al. GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study , 2007, European journal of haematology.
[10] C. Copie-Bergman,et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Vose,et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Bradstock,et al. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] F. Russo,et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Zelenetz,et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.
[16] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[17] C. Bokemeyer,et al. Therapy‐related malignancies following treatment of germ cell cancer , 1999, International journal of cancer.
[18] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Bokemeyer,et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Crump,et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[22] W Hop,et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Tucker,et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] W. Wilson,et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] De Ridder,et al. Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin ' s Lymphoma Using CHOP Versus CNOP Chemotherapy , 2007 .
[26] S. Jagannath,et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). , 1988, Blood.
[27] D.,et al. Regression Models and Life-Tables , 2022 .